Our recent studies demonstrated that the acquisition of CD146 and ABCB5 as melanoma-specific targets allows the isolation of highly primitive rare stem/mesenchymal CMCs (CD45−CD146+ABCB+) associated with disease progression. Here, MCAM is linked to melanoma.